DE60333476D1 - Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen - Google Patents

Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen

Info

Publication number: DE60333476D1
Authority: DE; Germany
Prior art keywords: treating; dependent symptoms; angiogenesis; compositions; plasmid dna
Prior art date: 2002-12-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60333476T

Other languages

English (en)

Inventor

Kazuya Hiraoka

Seiji Yamamoto

Yasufumi Kaneda

Toshio Ogihara

Ryuichi Morishita

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Anges Inc

Original Assignee

Anges MG Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-02

Filing date

2003-12-02

Publication date

2010-09-02

2003-12-02 Application filed by Anges MG Inc filed Critical Anges MG Inc

2010-09-02 Application granted granted Critical

2010-09-02 Publication of DE60333476D1 publication Critical patent/DE60333476D1/de

2023-12-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title 1
238000000034 method Methods 0.000 abstract 3
230000033115 angiogenesis Effects 0.000 abstract 2
230000001419 dependent effect Effects 0.000 abstract 2
239000013612 plasmid Substances 0.000 abstract 2
208000024891 symptom Diseases 0.000 abstract 2
208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 abstract 1
208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
208000031481 Pathologic Constriction Diseases 0.000 abstract 1
206010034576 Peripheral ischaemia Diseases 0.000 abstract 1
206010052428 Wound Diseases 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
206010008118 cerebral infarction Diseases 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
208000019622 heart disease Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
238000010255 intramuscular injection Methods 0.000 abstract 1
239000007927 intramuscular injection Substances 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
230000036262 stenosis Effects 0.000 abstract 1
208000037804 stenosis Diseases 0.000 abstract 1
238000001890 transfection Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Cardiology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Rheumatology (AREA)

DE60333476T 2002-12-02 2003-12-02 Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen Expired - Lifetime DE60333476D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43047802P	2002-12-02	2002-12-02
PCT/JP2003/015400 WO2004050126A2 (en)	2002-12-02	2003-12-02	Compositions for treating or preventing angiogenesis-dependent symptoms

Publications (1)

Publication Number	Publication Date
DE60333476D1 true DE60333476D1 (de)	2010-09-02

Family

ID=32469479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60333476T Expired - Lifetime DE60333476D1 (de)	2002-12-02	2003-12-02	Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen

Country Status (9)

Country	Link
US (1)	US7259149B2 (de)
EP (1)	EP1567197B1 (de)
JP (1)	JP4623719B2 (de)
CN (1)	CN1717254A (de)
AT (1)	ATE474604T1 (de)
AU (1)	AU2003302590B2 (de)
CA (1)	CA2507534A1 (de)
DE (1)	DE60333476D1 (de)
WO (1)	WO2004050126A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20010108053A (ko) *	1999-10-29	2001-12-07	무라야마 마사노리	당뇨병성 허혈성 질환 유전자 치료
US20090012498A1 (en) *	2004-10-29	2009-01-08	Yoshiki Sawa	Gene therapy for treatment of heart failure
US20090214496A1 (en) *	2006-01-30	2009-08-27	Licentia Ltd.	Bmx/etk tyrosine kinase gene therapy materials and methods
RU2542385C2 (ru) *	2012-08-31	2015-02-20	Общество с ограниченной ответственностью "НекстГен"	Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
RU2612497C2 (ru)	2015-05-26	2017-03-09	Общество с ограниченной ответственностью "НекстГен"	Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5941431U (ja) *	1982-09-07	1984-03-16	斎藤　春雄	治療用高圧タンクにおける緊急脱出扉装置
JPS6183121A (ja) *	1984-10-01	1986-04-26	Green Cross Corp:The	虚血性潰瘍治療剤
US20020137707A1 (en)	1997-12-30	2002-09-26	Monahan Sean D.	Intravascular delivery of non-viral nucleic acid
JP2001507207A (ja)	1996-05-01	2001-06-05	イマアーレクス・フアーマシユーチカル・コーポレーシヨン	化合物を細胞に送達する方法
US6312663B1 (en) *	1999-03-19	2001-11-06	Joseph V. Boykin, Jr.	Prediction of diabetes impaired wound healing by urinary nitrate assay
NZ514305A (en) *	1999-04-16	2004-01-30	Univ Yale	eNOS mutations useful for gene therapy and therapeutic screening
JP2001017188A (ja) *	1999-04-22	2001-01-23	Kyowa Hakko Kogyo Co Ltd	新規なｖｅｇｆ／ｐｄｇｆ様因子
EP1889633B1 (de) *	2000-06-27	2011-10-26	AnGes MG, Inc.	Medizinische Zusammensetzungen zur Angiogenese-Therapie
ES2527168T3 (es) *	2002-07-18	2015-01-21	Mitsubishi Rayon Co., Ltd.	Preimpregnado y procedimientos para la producción de materiales compuestos reforzados con fibras
JP4420633B2 (ja)	2002-08-08	2010-02-24	アンジェスＭｇ株式会社	血管新生治療剤
WO2004048435A1 (ja) *	2002-11-28	2004-06-10	Mitsubishi Rayon Co., Ltd.	プリプレグ用エポキシ樹脂、プリプレグ、繊維強化複合材料およびこれらの製造方法

2003
- 2003-12-02 CN CNA2003801045974A patent/CN1717254A/zh active Pending
- 2003-12-02 AT AT03812366T patent/ATE474604T1/de not_active IP Right Cessation
- 2003-12-02 JP JP2004556884A patent/JP4623719B2/ja not_active Expired - Lifetime
- 2003-12-02 AU AU2003302590A patent/AU2003302590B2/en not_active Ceased
- 2003-12-02 DE DE60333476T patent/DE60333476D1/de not_active Expired - Lifetime
- 2003-12-02 WO PCT/JP2003/015400 patent/WO2004050126A2/en active Application Filing
- 2003-12-02 EP EP03812366A patent/EP1567197B1/de not_active Expired - Lifetime
- 2003-12-02 US US10/536,274 patent/US7259149B2/en not_active Expired - Lifetime
- 2003-12-02 CA CA002507534A patent/CA2507534A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003302590B2 (en)	2008-11-06
US7259149B2 (en)	2007-08-21
ATE474604T1 (de)	2010-08-15
WO2004050126A2 (en)	2004-06-17
EP1567197A2 (de)	2005-08-31
AU2003302590A1 (en)	2004-06-23
WO2004050126A3 (en)	2004-09-30
JP2006511515A (ja)	2006-04-06
CN1717254A (zh)	2006-01-04
EP1567197B1 (de)	2010-07-21
CA2507534A1 (en)	2004-06-17
JP4623719B2 (ja)	2011-02-02
US20060135452A1 (en)	2006-06-22

Publication	Publication Date	Title
DE502005010615D1 (de)	2011-01-13	Mittel zur behandlung von entzündlichen erkrankungen
MX2010004074A (es)	2010-07-02	Combinacion 059.
BR0308928A (pt)	2005-01-04	Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
TW200502385A (en)	2005-01-16	Modulation of forkhead box o1a expression
AR047712A1 (es)	2006-02-15	Metodo de tratamiento de una lesion de tejido esqueletico blando natural administrando una composicion de celulas madre mesenquimatosas
DE602004012745D1 (de)	2008-05-08	Synergistische zusammensetzung zur behandlung von diabetes mellitus
ATE524546T1 (de)	2011-09-15	Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
BRPI0415533A (pt)	2006-12-26	método de terapia
ATE446102T1 (de)	2009-11-15	Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
ATE422357T1 (de)	2009-02-15	Verwendung von allopurinol zur behandlung von bluthochdruck
EA200700044A1 (ru)	2007-08-31	Композиция для местного применения
DE602005016198D1 (de)	2009-10-08	Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden
CY1111353T1 (el)	2015-08-05	Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
PL371205A1 (en)	2005-06-13	Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
DE60231050D1 (de)	2009-03-19	Verwendung von Totarol zur Behandlung von Pruritus
DE60333476D1 (de)	2010-09-02	Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen
ATE453402T1 (de)	2010-01-15	Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE289816T1 (de)	2005-03-15	Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
HK1087328A1 (en)	2006-10-13	Therapeutic composition for autoimmune conditions
ATE480232T1 (de)	2010-09-15	Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
IL164314A (en)	2010-11-30	Method to inhibit cell growth using oligonucleotides
ATE428437T1 (de)	2009-05-15	Dc-sign blockern und deren verwendung zur vorbeugung oder behandlung von viraleninfektionen
PL1599211T3 (pl)	2011-06-30	Zastosowanie izorhamnetyny do leczenia nastrojów i chorób depresyjnych
ATE537838T1 (de)	2012-01-15	Kombinationstherapie mit kloretazin(tm)
DE60128084D1 (de)	2007-06-06	Verwendung von inaktives cln2 proenzym zur behandlung von lincl